Variant Summary
- Also known as
- ETV6-NTRK3
- HGVS
- —
- Variant Type(s)
- transcript_fusion
- Evidence Items
- 30
Evidence Level Distribution
Level A: 3Level B: 9Level C: 13Level D: 5
Evidence Items
Showing CIViC evidence rows where gene = ETV6::NTRK3 and variant = Fusion.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| C | Predictive | Supports | Sensitivity/Response | Congenital Mesoblastic Nephroma | Larotrectinib | 4 |
| A | Predictive | Supports | Sensitivity/Response | Congenital Fibrosarcoma | Larotrectinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | B-lymphoblastic Leukemia/lymphoma | Larotrectinib | 4 |
| A | Diagnostic | Supports | Positive | Congenital Fibrosarcoma | 4 | |
| C | Predictive | Supports | Sensitivity/Response | B-lymphoblastic Leukemia/lymphoma | Methotrexate,Larotrectinib,Etoposide | 4 |
| D | Oncogenic | Supports | Oncogenicity | B-lymphoblastic Leukemia/lymphoma | 4 | |
| C | Oncogenic | Supports | Oncogenicity | Congenital Fibrosarcoma | 3 | |
| D | Oncogenic | Supports | Oncogenicity | Breast Secretory Carcinoma | 3 | |
| C | Predictive | Supports | Sensitivity/Response | Congenital Fibrosarcoma | Larotrectinib | 3 |
| B | Diagnostic | Supports | Positive | Congenital Mesoblastic Nephroma | 3 | |
| B | Diagnostic | Supports | Positive | Congenital Fibrosarcoma | 3 | |
| B | Diagnostic | Supports | Positive | Congenital Fibrosarcoma | 3 | |
| B | Diagnostic | Supports | Positive | Congenital Mesoblastic Nephroma | 3 | |
| B | Diagnostic | Supports | Positive | Breast Secretory Carcinoma | 3 | |
| B | Diagnostic | Supports | Positive | Breast Secretory Carcinoma | 3 | |
| B | Diagnostic | Supports | Positive | Breast Secretory Carcinoma | 3 | |
| C | Predictive | Supports | Sensitivity/Response | Glioblastoma | Entrectinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Melanoma | Entrectinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Mammary Analogue Secretory Carcinoma | Entrectinib | 3 |
| B | Prognostic | Supports | Poor Outcome | Papillary Thyroid Carcinoma | 3 | |
| C | Predictive | Supports | Sensitivity/Response | Breast Secretory Carcinoma | Larotrectinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Congenital Fibrosarcoma | Larotrectinib | 3 |
| A | Predictive | Supports | Sensitivity/Response | Solid Tumor | Larotrectinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | B-lymphoblastic Leukemia/lymphoma | Larotrectinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Entrectinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | B-lymphoblastic Leukemia/lymphoma | Larotrectinib | 3 |
| B | Diagnostic | Supports | Positive | Congenital Mesoblastic Nephroma | 2 | |
| C | Predictive | Supports | Sensitivity/Response | Anaplastic Astrocytoma | Entrectinib | 2 |
| C | Predictive | Does Not Support | Sensitivity/Response | Mammary Analogue Secretory Carcinoma | Crizotinib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Congenital Fibrosarcoma | Larotrectinib | 2 |